Elbasvir
A hepatitis C virus nonstructural protein 5A inhibitor.
General information
Elbasvir is a heterotetracyclic hepatitis C virus (HCV) nonstructural protein 5A inhibitor. It is used for the treatment of chronic HCV infection in a combined therapy (ChEBI).
Elbasvir on DrugBank
Elbasvir on PubChem
Elbasvir on Wikipedia
Marketed as
ZEPATIER (in a fixed dose with GRAZOPREVIR)
CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C5=C4)C=CC(=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@H](C(C)C)NC(=O)OC)C9=CC=CC=C9)NC(=O)OC
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
CSF3 Is a Potential Drug Target for the Treatment of COVID-19
Small molecule In vitro In silico |
16+ years old volunteers | 3.37 | Decreased host CSF3 protein expression in vitro and was predicted to inhibit it. CSF3 was computationally modelled to represent a drug target for the treatment of COVID-19. |
Jan/22/2021 |
|
Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors
RdRpol Small molecule In vitro In silico |
in silico; Huh 7-hACE2 cells | 4.10 | Inhibited SARS-CoV-2 infection in a high content microscopy assay with an EC50 of ca. 23 μM and high selectivity (CC50 of ca. 118). The drug also displayed efficacy in a viral yield reduction assay with an estimated EC50 of >1000 μM. Based on computational modelling, the antiviral activity stems from RNA-dependent RNA polymerase inhibition. |
Mar/10/2021 |
